glossari
downstream
process
technic
step
includ
purif
step
bioprocess
product
harvest
purifi
product
metabol
engin
practic
optim
genet
regulatori
process
within
cell
increas
cell
product
certain
substanc
prophylact
medic
treatment
design
use
prevent
diseas
occur
transduct
process
introduc
foreign
dna
deliber
cell
use
viral
vector
transfect
process
introduc
foreign
dna
deliber
cell
use
nonvir
method
upstream
process
technic
step
bioprocess
cell
develop
product
harvest
includ
cell
cultur
step
virus
microscop
infecti
agent
exclus
intracellular
organ
depend
anim
plant
bacteri
cell
multipli
virus
one
nucleic
acid
rna
dna
enclos
within
protein
coat
protect
viral
gene
mani
virus
also
viral
envelop
cover
nucleocapsid
consist
host
cell
membran
lipid
protein
viral
glycoprotein
protect
virus
degrad
outsid
cell
help
attach
host
cell
membran
sinc
initi
discoveri
tobacco
mosaic
viru
martinu
beijerinck
virus
describ
detail
nonetheless
signific
progress
viru
identif
propag
possibl
upon
establish
cell
cultur
technolog
develop
anim
cell
cultur
gradual
replac
live
anim
prepar
viral
antigen
vaccin
recent
advanc
virolog
molecular
biolog
allow
develop
platform
product
viruslik
particl
vlp
vaccin
emerg
diseas
viral
vector
gene
therapi
vlp
compos
viral
structur
protein
express
recombin
system
form
multiprotein
structur
mimick
organ
conform
authent
nativ
virus
lack
viral
genom
sever
applic
propos
virus
vlp
vaccin
gene
therapi
drug
deliveri
nanotechnolog
bioweapon
among
other
chapter
aim
review
fundament
applic
product
strategi
virus
vlp
well
challeng
perspect
futur
classif
system
virus
consid
virus
dna
intermedi
rna
virus
virus
includ
group
vi
possess
ssrna
genom
replic
use
revers
transcriptas
virus
human
immunodefici
viru
hiv
simian
immunodefici
viru
siv
rou
sarcoma
viru
rsv
member
retrovirida
familyse
fig
b
includ
group
dsrna
virus
repres
larg
group
pathogen
whose
genom
monopartit
segment
fragment
virus
releas
free
dsrna
genom
infect
cell
requir
transcript
synthesi
new
dsrna
genom
take
place
confin
environ
reoviru
rotaviru
member
reovirida
famili
includ
group
tabl
contrast
dsrna
ssrna
virus
genom
ssrna
virus
infecti
icosahedr
ssrna
virus
repres
larg
fraction
virus
known
includ
import
human
pathogen
polioviru
human
rhinoviru
hepat
viru
norwalk
viru
astroviru
alphaviru
member
flavivirida
famili
carri
rnacontain
nucleocapsid
exampl
unlik
ssrna
virus
nucleoprotein
respons
protect
genom
nonspecif
cellular
rna
bind
express
ssrna
virus
thu
synthesi
progeni
virus
requir
capsid
protein
virus
specif
packag
viral
rna
genom
exclud
ubiquit
cellular
rna
group
iv
includ
flavivirida
hepat
c
viru
hcv
coronavirida
sever
acut
respiratori
syndrom
viru
sar
viru
picornavirida
astrovirida
togavirida
calicivirida
famili
tabl
character
nonseg
genom
remain
three
genom
compris
sens
rna
segment
respect
larg
group
sens
rna
virus
includ
highli
preval
human
pathogen
respiratori
syncyti
viru
influenza
human
parainfluenza
virus
two
deadli
human
pathogen
name
ebola
marburg
virus
virus
major
econom
impact
poultri
cattl
industri
name
newcastl
diseas
viru
ndv
rinderpest
viru
tabl
vlp
multimer
protein
complex
compos
viral
structur
protein
assembl
spontan
express
recombin
system
structur
mimic
organ
conform
authent
nativ
virus
lack
viral
genom
date
differ
type
virus
mimick
vlp
virus
singl
multipl
capsid
protein
without
lipid
envelop
tabl
nonenvelop
virus
nucleocapsid
form
singl
viral
encod
protein
thu
vlp
virus
rel
easi
gener
assembl
process
reli
sole
express
level
singl
protein
exampl
present
tabl
one
studi
vlp
structur
simpl
virus
human
papillomaviru
hpv
vlp
although
nativ
viru
contain
major
minor
capsid
protein
hpv
respect
hpvvlp
form
protein
organ
pentamer
capsom
canin
parvoviru
porcin
parvoviru
ppv
vlp
also
form
singl
protein
major
structur
protein
virus
vlp
normal
express
insect
cell
induc
high
immunogen
respons
case
ppvvlp
largescal
product
doabl
norwalk
viru
nv
vlp
vlp
hepat
e
viru
hev
chimer
vlp
simian
viru
constitut
exampl
express
insect
cell
nvvlp
extrem
use
sourc
diagnost
antigen
monitor
diseas
outbreak
sinc
nativ
viru
limit
growth
cell
cultur
particl
also
shown
effect
stimul
igg
iga
humor
respons
mice
preliminari
phase
trial
human
confirm
safe
effect
stimul
igg
iga
respons
truncat
form
hev
capsid
readili
assembl
vlp
insect
cell
yet
test
vaccin
mice
immun
studi
vlp
abl
induc
system
mucos
immun
respons
follow
oral
administr
final
genet
manipul
major
capsid
protein
possibl
accommod
foreign
peptid
surfac
protein
way
assembl
chimer
display
peptid
surfac
confer
chimer
essenti
featur
use
control
cell
typespecif
gene
deliveri
system
mani
pathogen
virus
surround
envelop
consist
host
cell
membran
lipid
protein
viral
glycoprotein
protein
target
neutral
antibodi
essenti
compon
vaccin
due
inher
properti
lipid
envelop
assembl
envelop
vlp
technic
complex
exampl
present
tabl
first
vlp
vaccin
produc
character
consist
spheric
particl
diamet
nm
form
surfac
antigen
hepat
b
viru
hbsag
coassembl
host
cellular
membran
meanwhil
sever
envelop
vlp
success
develop
hcvvlp
produc
baculovirusinsect
cell
system
coexpress
core
protein
vlp
ebola
marburg
viru
vaccin
candid
emerg
diseas
two
exampl
hcvvlp
test
mice
baboon
shown
effect
stimul
cellular
humor
immun
respons
vlp
ebola
marburg
viru
shown
protect
small
laboratori
anim
well
nonhuman
primat
lethal
challeng
ebola
andor
marburg
virus
hsvvlp
ndvvlp
hantaanvlp
rvfvvlp
exemplifi
envelop
vlp
success
express
assembl
baculovirusinsect
cell
system
substanti
effort
put
forward
recreat
envelop
sar
coronaviru
envelop
virus
retrovirida
famili
form
permit
effici
induct
broadli
neutral
antibodi
although
none
retrovirusderiv
vlp
gone
clinic
trial
yet
initi
experi
hivvlp
sivvlp
anim
model
look
promis
chimer
vlp
contain
gag
capsid
protein
siv
envelop
protein
hiv
rsvvlp
form
vitro
assembl
gag
protein
vlp
influenza
viru
subtyp
also
part
group
success
produc
vlp
lipid
envelop
vlp
compos
multipl
interact
capsid
protein
challeng
produc
form
one
two
major
capsid
protein
due
site
protein
express
protein
encod
multipl
discret
mrna
process
singl
polyprotein
tend
differenti
local
cell
significantli
affect
effici
assembl
process
thu
essenti
guarante
interact
capsid
protein
express
vicin
within
cell
assembl
vlp
express
one
structur
viral
protein
achiev
variou
member
picornavirida
polioviru
enteroviru
birnavirida
infecti
bursal
diseas
viru
famili
adenoassoci
viru
type
vlp
also
includ
categori
vlp
multipleprotein
layer
particl
produc
coinfect
insect
cell
recombin
baculoviru
code
adenoviru
capsid
protein
vlp
effici
produc
member
reovirida
famili
virus
consider
complex
mimic
character
multipl
concentr
layer
differ
capsid
protein
bluetongu
viru
btv
vlp
rotaviruslik
particl
rlp
two
case
intact
biolog
activ
btvvlp
produc
insect
cell
simultan
express
four
structur
protein
btv
use
multicistron
recombin
baculoviru
rlp
also
form
similar
way
rotaviru
consist
three
concentr
protein
layer
inner
core
middl
layer
polymorph
protein
extern
layer
form
glycoprotein
spike
treat
trypsin
cleav
allow
viru
bind
entri
cell
insid
core
small
amount
exist
constitut
less
total
viral
protein
although
consid
play
key
role
rlp
stabil
upon
assembl
consensu
suffici
form
triplelay
particl
structur
similar
nativ
viru
biolog
function
rlp
normal
express
baculovirusinsect
cell
system
coexpress
three
rotaviru
structur
protein
mention
divers
structur
normal
observ
end
cultur
indic
assembl
process
highli
ineffici
fig
particl
extens
use
studi
viru
structur
role
protein
viral
morphogenesi
protein
function
biochem
properti
viru
interact
mammalian
host
cell
proteinprotein
interact
review
palomar
ramirez
rlp
also
vaccin
candid
rotaviru
diseas
consid
safe
induc
robust
antibodi
respons
protect
anim
engin
includ
one
outer
capsid
protein
properli
formul
potent
adjuv
administ
intramuscularli
even
intrarect
immun
induc
local
mucos
respons
report
suffici
protect
rotaviru
infect
possibl
rlp
may
provid
viabl
altern
exist
live
viru
vaccin
recent
rais
efficaci
concern
develop
countri
bangladesh
south
africa
product
virus
initi
perform
use
natur
host
virus
upon
establish
cell
cultur
technolog
anim
cell
cultur
gradual
replac
live
anim
prepar
viral
antigen
vaccin
observ
ender
cowork
nonnerv
tissu
cultur
could
use
replic
produc
polioviru
pave
way
largescal
product
vaccin
discoveri
led
develop
first
commerci
product
gener
use
mammalian
cell
cultur
primari
monkey
kidney
cell
polioviru
vaccin
regrett
primari
monkey
kidney
cell
present
mani
drawback
rel
high
risk
contamin
adventiti
agent
contamin
variou
monkey
virus
shortag
donor
anim
use
endang
anim
cell
sourc
use
uncharacter
insuffici
character
cell
substrat
viru
product
limit
expans
obligatorili
adher
cell
growth
human
diploid
fibroblast
cell
babi
hamster
kidney
cell
establish
use
product
vaccin
rabi
viru
footandmouth
diseas
respect
nowaday
sever
licens
human
viral
vaccin
produc
use
cell
substrat
see
tabl
clinic
trial
influenza
vaccin
produc
use
vero
madindarbi
canin
kidney
mdck
cell
among
other
despit
signific
advanc
vaccin
manufactur
vaccin
still
produc
egg
recent
approv
influenza
monoval
vaccin
csl
medimmun
llc
novarti
vaccin
diagnost
virus
may
also
serv
purpos
vaccin
product
platform
fact
virus
adenoviru
retroviru
lentiviru
adenoassoci
viru
commonli
use
gene
deliveri
vector
gene
therapi
among
applic
see
section
common
welldocu
packag
cell
line
adenoviru
product
human
embryon
kidney
hek
cell
line
contain
region
adenoviru
homolog
recombin
left
terminu
firstgener
adenoviru
vector
helper
viru
dna
partial
overlap
sequenc
genom
hek
cell
normal
lead
gener
replicativecompet
adenovirus
rca
presenc
rca
clearli
undesir
may
replic
uncontrol
manner
recombin
adenoviru
batch
use
human
patient
rca
potenti
hazard
especi
immunocompromis
patient
associ
inflammatori
respons
altern
host
cell
line
develop
overcom
problem
either
reduc
overlap
sequenc
elimin
overlap
case
cell
cell
line
deriv
human
embryon
retin
cell
establish
industri
applic
eg
full
traceabl
avail
due
reduc
propens
gener
rca
capac
achiev
high
yield
adenoviru
vector
anoth
disadvantag
human
adenoviru
vector
limit
clinic
use
popul
develop
preexist
humor
cellular
immun
vector
sustain
platform
gener
vector
differ
human
serotyp
deriv
nonhuman
adenoviru
titer
similar
greater
obtain
human
adenoviru
vector
free
detect
level
rca
requir
one
exampl
product
canin
adenoviru
type
vector
dog
kidney
cell
vector
risk
associ
rca
diminish
complet
elimin
vector
propag
human
cell
also
vector
transduc
humanderiv
cell
effici
similar
human
adenoviru
type
amen
vivo
use
novel
cell
line
emphasi
mdck
cell
product
vector
evalu
nih
mous
embryon
fibroblast
cell
line
ferret
brain
cell
line
human
cell
line
grow
suspens
cem
obligatori
suspens
cell
line
use
establish
retroviru
vector
produc
cell
line
detail
exampl
found
elsewher
recent
highli
versatil
produc
cell
line
develop
base
hek
cell
equip
flippas
recognit
target
site
contain
murin
leukemia
viru
mlv
green
fluoresc
protein
gfp
vector
cell
allow
effici
flp
recombinasemedi
cassett
exchang
mlv
vector
thu
cassett
exchang
tag
retroviru
produc
cell
clone
capabl
produc
vector
contain
transgen
choic
level
similar
observ
mother
produc
cell
line
major
problem
product
lentivirus
develop
packag
cell
line
stabl
express
lentiviru
particl
proven
difficult
oncovirus
partli
due
express
protein
rev
viral
proteas
appear
toxic
cell
consequ
lentivir
vector
produc
transient
transfect
highexpress
cell
line
co
gener
use
four
differ
plasmid
gagpol
env
rev
lvvector
lentivir
vector
also
produc
transduct
cell
baculovirus
sustain
transgen
express
observ
lentiviru
transduct
hela
cell
recombin
adenoassoci
viral
raav
vector
produc
use
stabl
cell
line
contain
requir
gene
transient
transfect
transient
transfect
employ
use
cell
cotransfect
two
plasmid
contain
raav
vector
rep
cap
gene
follow
infect
helper
viru
induc
replic
raav
anoth
possibl
cotransfect
cell
three
plasmid
contain
raav
vector
rep
cap
gene
adenoviru
helper
gene
stabl
cell
line
hand
requir
presenc
helper
viru
initi
raav
product
sinc
alreadi
contain
raav
vector
rep
cap
gene
adenoassoci
viru
possibl
use
hela
common
cell
stabl
cell
line
system
better
suit
largescal
product
raav
transient
transfect
nevertheless
gener
stabl
cell
line
tediou
time
consum
estim
raav
particl
requir
clinic
human
use
independ
product
strategi
maximum
raav
titer
typic
around
infecti
particl
ip
per
ml
clearli
insuffici
fulfil
need
order
overcom
limit
recent
studi
focus
produc
raav
vector
insect
cell
cultur
use
recombin
baculoviru
system
product
raav
particl
achiev
coinfect
spodoptera
frugiperda
sf
cell
three
baculoviru
vector
bacrep
baccap
bacraav
encod
respect
compon
raav
product
machineri
system
lend
largescal
product
serumfre
condit
cell
grown
suspens
popular
express
system
product
vlp
yeast
system
due
easi
protein
express
abil
scale
cost
product
howev
appropri
posttransl
modif
ptm
protein
glycosyl
correct
protein
fold
protein
assembl
codon
optim
may
dictat
altern
product
system
within
mammalian
cell
line
either
transient
stabli
transfect
transduc
viral
express
vector
baculovirusinsect
cell
system
variou
speci
bacteria
plant
cell
receiv
special
attent
tabl
polyomavirusvlp
noroviru
vlp
hcvvlp
investig
vlp
produc
bacteria
ie
escherichia
coli
yet
reach
market
fact
littl
immunogen
inform
avail
hbvvlp
hpvvlp
hcvvlp
ebolavlp
rsvvlp
infecti
hypoderm
hematopoiet
necrosi
virusvlp
novlp
indian
peanut
clump
virusvlp
due
inabl
protein
express
prokaryot
cell
undergo
ptm
protein
glycosyl
key
featur
vlpderiv
vaccin
anoth
common
difficulti
cell
express
solubl
fulllength
product
free
toxin
heat
shock
protein
hsp
chaperon
protein
sinc
limit
solubl
recombin
viral
protein
promot
format
inclus
bodi
downstream
process
significantli
compromis
consequ
process
rout
becom
potenti
expens
eukaryot
rout
even
downstream
process
solubl
fraction
vlp
precursor
often
requir
separ
hsp
molecular
chaperon
protein
eg
groel
remain
attach
capsomer
creat
signific
biosepar
problem
proteas
degrad
codon
bia
also
sourc
reduc
manufactur
precis
contribut
lower
yield
possibl
nonhomogen
final
vlp
architectur
overcom
limit
express
system
baculovirusinsect
cell
system
use
instead
bacteria
yeast
anoth
altern
disassembl
reassembl
vlp
vitro
method
describ
detail
follow
section
vlp
form
sever
protein
requir
simultan
express
multipl
protein
versatil
effici
system
product
recombin
protein
baculovirusinsect
cell
system
insect
cell
initi
grown
desir
cell
concentr
infect
one
sever
recombin
baculovirus
contain
gene
gene
code
protein
interest
construct
recombin
baculoviru
simpl
fast
provid
high
versatil
express
system
rapid
construct
import
produc
vaccin
rapidli
chang
virus
fundament
requir
effici
approach
contend
potenti
pandem
time
manner
instanc
influenza
vaccin
product
campaign
base
baculovirusinsect
cell
system
complet
within
month
identifi
particular
circul
viral
strain
wherea
eggbas
cell
culturebas
platform
would
requir
month
list
vlp
produc
use
system
shown
tabl
protein
express
mammalian
cell
cultur
system
undergo
complex
ptm
copi
natur
signific
advantag
system
limit
highmannos
glycoprotein
modif
baculovirusinsect
cell
system
yeast
incap
type
ptm
bacteria
thu
assembl
protein
vlp
close
resembl
format
nativ
viru
particl
main
disadvantag
system
low
control
high
product
cost
differ
mammalian
cell
use
vlp
product
exampl
vero
cell
abl
produc
vlp
infect
recombin
vaccinia
vector
carri
gene
code
viral
protein
differ
virus
vlp
also
produc
stabli
transient
transfect
cho
cell
wang
et
al
use
recombin
baculoviru
transduc
hela
bhk
primari
rat
articular
chondrocyt
cell
recent
advanc
plant
biotechnolog
made
possibl
use
transgen
plant
potenti
viabl
altern
cell
cultur
system
product
recombin
edibl
subunit
vaccin
hbvvlp
nvvlp
studi
vlp
produc
three
differ
speci
transgen
plant
solanum
tuberosum
potato
lycopersicon
esculentum
tomato
nicotiana
benthamiana
tobacco
edibl
plant
offer
palat
oral
deliveri
system
would
preclud
costli
purif
process
inject
vaccin
theori
scaleup
product
would
requir
larg
invest
hardwar
cultur
media
resourc
would
need
agricultur
practic
stabl
transgen
line
acreag
cultiv
main
disadvantag
use
transgen
plant
low
express
level
obtain
antigen
degrad
take
place
vivo
deliveri
main
area
applic
anim
bacteri
plant
algal
virus
includ
vaccin
develop
gene
therapi
vaccin
base
live
virus
tradit
effect
rel
easi
produc
elimin
smallpox
accomplish
mass
vaccin
live
vaccinia
viru
mildli
pathogen
anim
viru
relat
smallpox
likewis
live
attenu
vaccin
well
toler
highli
immunogen
live
attenu
polioviru
vaccin
develop
dr
albert
sabin
erad
poliomyel
diseas
western
hemispher
drastic
reduc
incid
rate
worldwid
vaccin
infecti
diseas
yellow
fever
typhoid
fever
mump
shigella
also
base
live
attenu
virus
attenu
virus
accomplish
one
follow
method
attenu
pathogen
physic
mean
select
natur
occur
mutant
lead
infect
abort
replic
pathogen
retain
immunogen
inactiv
kill
vaccin
also
stimul
protect
immun
respons
inactiv
polioviru
vaccin
ipol
sanofi
pasteur
sa
influenza
vaccin
fluarix
glaxosmithklin
typhoid
fever
vaccin
typhim
vi
sanofi
pasteur
msd
constitut
exampl
diseasecaus
organ
inactiv
chemic
formaldehyd
main
drawback
vaccin
requir
boost
continu
effici
immun
respons
nowaday
use
molecular
biolog
dna
manipul
method
possibl
express
protect
protein
adequ
live
vector
purpos
design
live
vaccin
variou
type
pathogen
addit
develop
revers
genet
system
recoveri
virus
cdna
made
possibl
rapidli
gener
recombin
attenu
deriv
tabl
list
exampl
current
licens
viral
vaccin
late
earli
emerg
techniqu
subclon
mammalian
gene
prokaryot
plasmid
bacteriophag
correctli
foreseen
steppingston
precursor
techniqu
human
gene
therapi
parallel
investig
biolog
avian
murin
oncoretrovirus
led
develop
retrovir
vector
began
use
tool
gene
transfer
mammalian
cell
first
human
trial
gene
transfer
carri
late
treatment
patient
advanc
metastat
cancer
process
consist
introduc
gene
code
neomycin
resist
human
tumorinfiltr
lymphocyt
retroviralmedi
gene
transduct
infus
patient
thu
use
new
gene
marker
infus
cell
sinc
remark
expans
number
vector
system
avail
express
human
gene
directli
associ
diseas
state
therapeut
purpos
gene
therapi
trial
use
retrovir
vector
treat
xlink
sever
combin
immunodefici
xscid
constitut
success
applic
gene
therapi
date
scid
diseas
patient
neither
cellmedi
immun
respons
abil
gener
antibodi
high
rate
immun
system
reconstitut
observ
patient
treat
xscid
gene
therapi
trial
patient
develop
leukemialik
ill
fulli
recov
convent
antileukemia
treatment
despit
result
gene
therapi
trial
treat
scid
due
defici
adenosin
deaminas
enzym
continu
rel
success
unit
state
franc
unit
kingdom
itali
japan
last
decad
process
retrovir
vector
product
consider
investig
present
mani
difficulti
mainli
due
vector
instabl
low
cell
product
hamper
attain
high
viral
titer
strategi
base
manipul
sugar
carbon
sourc
lipid
temperatur
osmot
pressur
use
bioreact
establish
pioneer
packag
cell
line
flex
show
potenti
increas
yield
infecti
retrovir
vector
allow
gener
highqual
clinic
prepar
gene
therapi
applic
adenoviru
vector
also
effici
vehicl
deliv
nucleic
acid
mammalian
cell
human
adenoviru
type
use
vector
backbon
adenovirusmedi
gene
transfer
howev
due
number
signific
disadvantag
need
immunosuppress
toler
patient
potenti
debilit
viru
vector
differ
serotyp
deriv
nonhuman
adenoviru
bovin
sheep
bird
develop
recent
vector
produc
dog
kidney
cell
gain
increas
attent
due
emerg
potenti
studi
pathophysiolog
potenti
treatment
neurodegen
diseas
like
parkinson
alzheim
huntington
among
other
first
clinic
trial
use
recombin
adenoviru
carri
cystic
fibrosi
cf
patient
two
year
later
first
recombin
adenoassoci
viru
trial
initi
cf
patient
trial
hemophilia
b
patient
commenc
shortli
inevit
lentiviru
recombin
herpesviru
vector
also
enter
clinic
trial
four
viral
vector
system
mention
highli
effici
system
gene
transfer
express
vivo
nondivid
cell
fact
viral
vector
current
undergo
clinic
trial
adenoviru
retroviru
adenoassoci
viru
hsv
detail
descript
cell
line
use
product
vector
respect
product
strategi
present
tabl
due
inabl
replic
absenc
toxic
mammalian
cell
baculovir
vector
emerg
gene
therapi
vehicl
treatment
wide
rang
human
diseas
recent
genet
modifi
recombin
baculoviru
encod
cherryr
fluoresc
protein
control
strong
mammalian
cell
promot
cytomegaloviru
promot
prove
effect
transduc
human
liver
carcinoma
cell
line
studi
indic
baculovirus
show
promis
gene
express
effici
liver
skelet
muscl
brain
eye
importantli
baculovir
vector
present
effici
similar
adenovir
vector
transduc
human
smooth
muscl
cell
human
cardiomyocyt
fibroblast
major
challeng
product
high
titer
recombin
baculoviru
although
metabol
engin
approach
shown
improv
baculoviru
titer
high
cell
densiti
platform
product
baculovir
vector
use
gene
therapi
clinic
trial
yet
implement
vlp
use
prophylact
therapeut
vaccin
wide
varieti
diseas
recent
develop
molecular
biolog
virolog
renew
interest
vlp
versatil
system
gene
drug
deliveri
vlp
use
vaccin
normal
devoid
dna
viral
cellular
origin
vlp
produc
capsid
envelop
protein
wide
varieti
virus
purpos
studi
viral
assembl
develop
vaccin
hbvvlp
hpvvlp
success
vaccin
vlpbase
vaccin
pathogen
directli
affect
immun
cell
success
evad
immun
system
hcv
prove
extrem
difficult
develop
anoth
import
forthcom
applic
vlp
use
gener
immun
respons
foreign
protein
epitop
fuse
coupl
vlp
differ
origin
result
socal
chimer
vlp
tabl
vaccin
hpv
infect
exampl
chimer
vlp
protein
epitop
insert
protein
confer
protect
broader
rang
hpv
type
end
tailor
vlp
depend
final
applic
vaccin
prophylact
therapeut
may
requir
adapt
structur
particl
size
envelop
structur
etc
target
host
dendrit
cell
mucos
surfac
etc
rout
administr
intranas
intramuscular
etc
achiev
desir
immun
respons
cancer
immunotherapi
tcell
respons
often
desir
bcell
respons
addit
tcell
epitop
local
insid
vlp
avoid
interfer
vlp
uptak
natur
receptor
nativ
viru
thu
vlp
vaccin
candid
necessarili
display
surfacespecif
epitop
order
recogn
immun
system
case
hpv
vlp
hbvvlp
first
case
hpv
andor
peptid
contain
tcell
epitop
fuse
hpv
protein
insert
vlp
second
case
hpv
epitop
insert
surfac
core
protein
hbvvlp
hpvvlp
shown
induc
cytotox
cell
protect
mice
challeng
hpv
tumor
result
purifi
chimer
hbvvlp
also
confirm
high
immunogen
mice
vlp
common
featur
induc
immun
respons
nonselfantigen
except
conjug
vlp
howev
immun
therapi
cancer
nonvir
origin
strategi
induc
immun
respons
selfantigen
one
studi
epitop
deriv
ovalbumin
wellstudi
melanoma
tumor
antigen
insert
directli
murin
polyomavirusvlp
vlp
carri
ovalbumin
epitop
inject
mice
therapeut
set
two
inject
melanoma
tumor
challeng
complet
protect
tumor
develop
obtain
induct
cell
specif
ovalbumin
epitop
demonstr
mani
capsid
protein
use
vlp
format
hpv
polyomaviru
abil
bind
nonspecif
viral
cellular
dna
demonstr
murin
polyomavirusvlp
could
packag
viral
dna
transduc
cell
vitro
result
express
viral
gene
product
later
experi
plasmid
dna
demonstr
feasibl
use
vlp
gene
transfer
sinc
number
studi
perform
order
evalu
optim
dna
packag
transduct
vlp
deriv
differ
member
polyomavirida
famili
exampl
produc
baculovirusinsect
cell
system
use
effici
methodolog
vitro
packag
plasmid
less
kb
proven
effici
gene
deliveri
vivo
anoth
exampl
jc
polyomavirusvlp
produc
baculovirusinsect
cell
system
vlp
disassembl
pentam
reassembl
vitro
possibl
insert
kb
dna
fragment
code
enhanc
green
fluoresc
protein
egfp
insid
jc
polyomavirusvlp
vlp
transduct
result
cell
measur
flow
cytometri
show
cell
express
egfp
protein
epitop
small
molecul
attach
surfac
alreadi
form
purifi
vlp
present
advantag
vlpform
method
directli
insert
epitop
vlp
protein
one
advantag
alreadi
form
vlp
use
basi
attach
number
differ
drug
either
protein
smaller
molecul
provid
flexibl
platform
drug
deliveri
second
attach
molecul
may
provid
stronger
effici
immun
respons
due
local
vlp
surfac
one
exampl
attach
peptid
small
molecul
vlp
consist
coat
protein
bacteriophag
qb
vlp
develop
gener
antibodi
respons
nicotin
angiotensin
ii
phase
trial
healthi
nonsmok
vaccin
nicotineconjug
qbvlp
demonstr
strong
nicotinespecif
igmigg
respons
noteworthi
nicotin
per
se
induc
antibodi
respons
conjug
vlp
nicotin
potenti
help
smoker
quit
smoke
reduc
satisfact
deriv
nicotin
intak
phase
ii
clinic
trial
increas
longterm
abstin
observ
smoker
attain
high
antibodi
level
follow
vaccin
platform
use
coupl
molecul
peptid
vlp
rheumatoid
arthriti
alzheim
treatment
respect
peacey
et
al
genet
modifi
rabbit
hemorrhag
diseas
viru
rhdv
vlp
variou
short
peptid
sequenc
capabl
present
recogn
immun
cell
howev
approach
limit
includ
time
involv
engin
chimer
vlp
size
constraint
impos
introduc
peptid
increas
instabl
modifi
capsid
lead
limit
yield
inaccess
alter
conform
introduc
residu
overcom
difficulti
chemic
linker
use
coval
conjug
small
peptid
whole
protein
rhdvvlp
scaffold
rapid
approach
enabl
surfac
conjug
substanti
rang
antigen
without
constraint
impos
subunit
fold
vlp
format
attach
antigen
rhdvvlp
confer
immunostimulatori
properti
underli
viral
shell
conjug
antigen
enabl
initi
antigenspecif
humor
cellmedi
immun
respons
result
demonstr
rhdvvlp
util
versatil
molecular
scaffold
mani
applic
vaccin
develop
biolog
nanotechnolog
drug
deliveri
may
also
achiev
vlp
carri
desir
drug
insid
capsid
accomplish
exampl
step
vitro
disassembl
reassembl
lee
tan
success
encapsul
gfp
insid
hbvvlp
disassembl
vlp
monom
urea
follow
reassembl
use
dialysi
gfp
molecul
virus
vlp
success
produc
vivo
vitro
sinc
begin
centuri
late
respect
product
bioproduct
involv
sever
bioengin
issu
must
care
address
order
control
upstream
downstream
process
maxim
perform
reduc
product
cost
product
yield
strongli
depend
product
strategi
chosen
batch
fedbatch
continu
perfus
strategi
normal
use
product
virus
vlp
batch
product
import
control
accumul
toxic
product
well
deplet
essenti
nutrient
cellular
growth
deplet
avoid
select
addit
nutrient
glucos
glutamin
andor
amino
acid
complet
medium
addit
use
fedbatch
strategi
yield
significantli
improv
scaleup
becom
difficult
expens
sinc
cultur
medium
ineffici
use
altern
continu
system
present
short
throughput
time
small
number
product
step
nonetheless
continu
reactor
oper
long
period
month
prone
gener
defect
virus
either
directli
reduc
viral
yield
indirectli
impact
vlp
yield
compet
host
cell
protein
express
machineri
addit
complex
bioproduct
produc
system
gener
low
constitut
major
drawback
compar
system
perfus
strategi
enhanc
cellular
growth
product
yield
howev
perfus
requir
use
larg
volum
media
significantli
increas
product
cost
addit
devic
use
separ
cell
medium
difficult
scale
normal
induc
cellular
damag
impact
neg
cellular
growth
rate
subsequ
viral
vlp
product
rate
envirom
envirom
affect
viral
replic
vlp
product
level
cellular
growth
metabol
state
dna
transcript
replic
mrna
translat
protein
ptm
among
other
envirom
enfold
dissolv
oxygen
concentr
ph
temperatur
agit
rate
cell
substrat
concentr
inlet
ga
flow
composit
volum
pressur
fluid
dynam
power
input
osmolar
variabl
differ
process
process
possibl
monitor
control
situ
continu
adjust
bioreactor
paramet
certain
predetermin
set
point
exampl
recombin
protein
product
insect
cell
maintain
constant
osmolar
mosm
osmolar
fall
rang
mosm
product
significantli
reduc
depend
sensit
cell
line
use
stress
gener
sparg
bubbl
entrain
agit
may
impact
neg
viral
vlp
product
spargingrel
stress
allevi
use
head
space
aerat
albeit
product
achiev
cultur
system
remark
lower
valid
solut
use
nonion
copolym
pluron
lower
cultur
medium
surfac
tension
imped
attach
cell
bubbl
liber
lethal
energi
burst
pluron
also
interact
cell
membran
increas
rigid
make
resist
hydrodynam
forc
oxygen
limit
excess
induc
proteas
synthesi
subsequ
degrad
product
interest
concomitantli
oxygenderiv
free
radic
present
high
level
dissolv
oxygen
tension
caus
oxid
stress
cell
oxid
damag
protein
also
import
bear
mind
temperatur
fluctuat
induc
differ
oxygen
solubl
level
increas
temperatur
induc
lower
oxygen
solubl
absenc
contamin
protein
dna
host
viral
absenc
incorrectli
assembl
macrostructur
endotoxin
level
specifi
regulatori
agenc
food
drug
administr
fda
european
medicin
agenc
emea
ensur
qualiti
efficaci
downstream
process
critic
success
process
technolog
use
particularli
challeng
task
case
produc
virus
vlp
differ
significantli
size
molecular
weight
protein
complex
defect
virus
need
remov
natur
bioproduct
either
extracellular
associ
cellular
structur
also
influenc
purif
strategi
product
secret
media
easili
process
sinc
requir
high
number
purif
step
produc
intracellularli
extract
prior
purif
essenti
case
fusion
tag
use
facilit
monitor
downstream
process
nonetheless
care
must
taken
place
fusion
tag
may
affect
viru
matur
protein
express
indirectli
compromis
biolog
activ
medium
contain
serum
major
problem
high
protein
content
complic
downstream
process
use
serumfre
medium
recommend
contain
animalderiv
supplement
pose
safeti
concern
facilit
downstream
oper
natur
outer
protein
virus
vlp
confer
bioproduct
specif
uniqu
characterist
strongli
impact
design
downstream
strategi
end
clear
trend
downstream
process
classic
laboratori
purif
method
like
sucros
cesium
chlorid
gradient
centrifug
toward
sophist
techniqu
like
tangenti
flow
filtrat
gel
permeat
chromatographi
liquid
chromatographi
ion
exchang
chromatographi
affin
chromatographi
sizeexclus
chromatographi
includ
use
newer
dispos
membran
technolog
heterolog
protein
basi
viral
particl
vlp
normal
express
transfect
transient
stabl
system
transduct
use
viral
express
vector
avail
stabl
packag
cell
line
capabl
continu
express
specif
gene
repres
step
toward
scaledup
product
viral
vector
stock
use
drug
deliveri
system
applic
gene
therapi
although
product
viral
vector
produc
cell
line
remain
lower
expect
gener
accept
viral
yield
express
secret
insolubl
protein
normal
favor
stabl
transfect
cell
line
use
constitut
activ
promot
integr
genom
requir
infect
activ
essenti
applic
protein
character
highthroughput
screen
gene
function
transient
transfect
appropri
use
viral
express
vector
viru
andor
protein
synthesi
anoth
altern
although
requir
addit
alway
fiddli
step
viral
infect
viral
yield
high
ip
ml
report
baculoviru
adenoviru
product
protein
express
level
mg
l
strength
promot
control
protein
express
either
viru
encapsul
vlp
assembl
well
time
promot
becom
activ
drive
product
level
thu
optim
promot
strength
must
care
evalu
common
strong
promot
overwhelm
process
capac
endoplasm
reticulum
thu
reduc
final
yield
inde
secret
complet
complex
glycosyl
recombin
protein
baculovirusinsect
cell
system
improv
gene
control
promot
instead
stronger
polyhedrin
promot
use
earli
instead
late
late
promot
difficult
choic
late
promot
express
protein
occur
toward
end
cultur
cell
death
phase
proteas
influenc
correct
protein
ptm
neg
impact
final
yield
hand
earli
promot
induc
lower
protein
product
case
enzym
transcript
factor
necessari
protein
express
yet
fulli
activ
earli
stage
combin
promot
strength
correct
time
promot
activ
essenti
assess
high
product
yield
mathemat
model
intracellular
event
use
identifi
best
strategi
obtain
optim
stoichiometri
thermodynam
condit
vlp
assembl
determin
attain
optim
yield
robust
product
system
moi
use
depend
target
product
product
process
dimens
viral
stock
normal
reli
predict
poisson
distribut
low
moi
viru
per
cell
advantag
requir
low
concentr
virus
number
virus
normal
insuffici
infect
cell
thu
high
percentag
cell
remain
healthi
grow
upon
initi
infect
steep
increas
infect
cell
concentr
observ
second
gener
virus
start
infect
uninfect
cell
popul
end
bioreact
concentr
infect
cell
suffici
high
sustain
product
virus
vlp
high
level
main
drawback
action
proteas
sinc
overal
process
infect
plu
viral
andor
protein
synthesi
slow
bioproduct
expos
cellular
proteas
long
period
time
may
compromis
qualiti
quantiti
final
product
contrari
high
moi
viru
per
cell
requir
larg
viral
stock
favor
select
fastrepl
defect
viru
addit
volumetr
yield
consider
lower
achiev
low
moi
result
lower
concentr
infect
cell
end
bioreact
theori
differ
could
compens
increas
cci
howev
high
cci
chang
cell
energet
state
upon
infect
induc
signific
drop
cellspecif
product
medium
replac
toi
use
fedbatch
perfus
cultur
strategi
capabl
maintain
specif
product
similar
report
low
cci
major
inconveni
neither
practic
necessarili
econom
larg
scale
creat
opportun
develop
novel
techniqu
process
optim
base
metabol
engin
system
biolog
anoth
import
paramet
toh
delay
harvest
time
increas
exposur
virus
vlp
intracellular
extracellular
proteas
induc
pronounc
cell
lysi
addit
releas
contamin
protein
degrad
host
viral
dna
cell
compart
viral
protein
macrostructur
extracellular
medium
complic
downstream
process
product
interest
optim
harvest
time
normal
hpi
hour
postinfect
cell
viabil
interplay
abovement
paramet
complex
normal
requir
substanti
experiment
avoid
mathemat
model
use
significantli
reduc
amount
work
requir
assist
definit
optim
processrel
paramet
moi
toi
toh
cci
complex
biolog
system
maxim
process
perform
commerci
success
bioproduct
requir
control
monitor
process
wellcharacter
product
unfortun
monitor
system
character
techniqu
complic
handl
extrem
costli
semiquantit
mani
case
nonexist
significantli
compromis
robust
scalabl
process
viral
quantif
accur
method
measur
infecti
total
particl
titrat
assay
plaqueform
unit
assay
growth
cessat
cell
size
assay
alamar
blue
assay
tissu
cultur
infecti
dose
microcultur
tetrazolium
assay
revers
transcriptas
activ
assay
electron
microscopi
directli
indirectli
assess
viral
titer
either
infecti
total
particl
simultan
method
flow
cytometri
realtim
quantit
polymeras
chain
reaction
qpcr
immunoblot
highperform
liquid
chromatographi
hplc
semiquantit
end
appropri
titrat
method
depend
type
viru
detect
system
avail
quantif
vlp
involv
higher
degre
complex
method
base
immunoassay
western
blot
enzymelink
immunosorb
assay
elisa
bicinchonin
acid
bca
protein
quantif
assay
electron
microscopi
realtim
qpcr
altern
howev
method
semiquantit
unabl
differenti
protein
part
correctli
assembl
vlp
other
incomplet
vlp
viral
particl
macromolecular
structur
thu
overestim
underestim
vlp
yield
frequent
obtain
recent
develop
method
gelperm
hplc
sodium
dodecyl
sulfatecapillari
gel
electrophoresi
new
applic
intact
cell
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
methodolog
capillari
zone
electrophoresi
may
allow
simpl
fast
lowcost
quantif
viral
protein
vlp
purifi
bulk
sampl
near
futur
develop
novel
detect
sensor
base
acoust
reson
turbid
fluoresc
possibl
monitor
kinet
vlp
format
situ
onlin
alreadi
possibl
wide
varieti
cultur
constitu
one
techniqu
twodimension
fluorometri
use
optic
fiber
technolog
allow
simultan
monitor
sever
compound
present
outsid
envirom
insid
metabolom
cell
assembl
viral
particl
vlp
spheric
polymersclos
structur
compos
sever
protein
subunitsi
poorli
understood
littl
experiment
inform
describ
intraand
intersubunit
bind
energi
rate
order
assembl
reaction
format
nucleat
structur
last
decad
mathemat
model
becom
promin
reliabl
sourc
knowledg
understand
drive
build
viru
capsid
polyhedr
protein
macrostructur
mani
mathemat
model
propos
base
theoret
constant
associ
dissoci
k
n
k
app
respect
free
energi
associ
intersubunit
contact
dg
c
assembl
pathway
way
constant
energi
relat
specif
cultur
paramet
ph
calcium
concentr
ionic
strength
other
need
better
understood
vitro
experi
assembl
disassembl
vlp
help
assess
kind
relationship
recent
studi
vitro
disassembl
rlp
triplelay
particl
dlp
doublelay
particl
assembl
dlp
monom
rlp
address
effect
physicochem
paramet
ph
ionic
strength
temperatur
format
stabil
rlp
dlp
result
indic
particl
stabl
within
specif
ph
temperatur
rang
c
outsid
threshold
particl
aggreg
c
disassembl
c
instabl
isoelectr
point
becom
evid
addit
reaction
rate
rlp
disassembl
correl
temperatur
ionic
strength
low
temperatur
low
ionic
strength
induc
low
disassembl
reaction
rate
hand
rlp
assembl
reaction
rate
decreas
increas
ph
ionic
strength
temperatur
calcium
concentr
find
clearli
demonstr
process
optim
complex
protein
macrostructur
feasibl
manipul
physicochem
paramet
nonetheless
care
must
taken
extrapol
vitro
result
vivo
experi
case
best
condit
subunit
interact
particl
format
due
differ
environment
cultur
condit
two
system
virus
vlp
proteinrel
macrostructur
preferenti
vehicl
mani
applic
complex
product
design
effici
upstream
downstream
strategi
definit
appropri
qualiti
control
monitor
method
attain
high
product
complic
essenti
thu
imper
constrain
envirom
effect
qualiti
quantiti
product
viral
particl
vlp
use
respect
area
applic
virus
wide
use
gene
therapi
highthroughput
screen
gene
function
drug
deliveri
vitro
assembl
studi
design
antivir
drug
recombin
protein
product
bioinsecticid
bioweapon
prepar
materi
scienc
engin
build
block
electron
biosensor
chemistri
vlp
hand
establish
power
tool
vaccin
develop
furthermor
improv
knowledg
point
toward
larger
promis
applic
viru
vlp
platform
area
research
near
futur
nanotechnolog
use
tool
biomed
scienc
